Developer docs
API playgroundTry for free, no card

Search company profiles

Eligo Bioscience

Full company profile

uuid0000k7l

Namestring
Eligo Bioscience
Legal namestring
Eligo Bioscience SA
Websiteurl
eligo.bio
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Eligo Bioscience is a privately held, clinical-stage biotechnology company headquartered in Paris, France, developing a proprietary platform for in vivo gene editing of the microbiome. Founded in 2015 by CRISPR pioneers from The Rockefeller University and MIT, the company's Eligobiotics platform uses engineered phage-derived particles to deliver DNA payloads — including CRISPR-Cas nucleases, base editors, and therapeutic genes — directly into bacterial populations in the body, enabling precise, strain-specific modification or elimination of targeted bacteria without affecting beneficial commensals.

The platform comprises three core modalities: SSAM (Sequence-Specific Anti-Microbials) for CRISPR-based killing of harmful bacteria, GEM (Genome Editing of the Microbiome) for base editing of bacterial DNA without killing the cells, and FAME (Function Addition to the Microbiome) for programming commensal bacteria to express therapeutic proteins. Its lead programs are EB003, an oral candidate for Shiga-toxin producing E. coli infection leading to Hemolytic Uremic Syndrome (FDA Orphan Drug, Rare Pediatric Disease, and EMA Orphan Designations), and EB005, a topical candidate for moderate-to-severe acne vulgaris developed in partnership with GSK in a deal worth up to $224 million.

Eligo has no commercialized products and operates a pre-revenue business model that combines pharmaceutical licensing and co-development partnerships (e.g., GSK), non-dilutive grants from the French government (France 2030), the European Commission, and CARB-X, and venture financing from Khosla Ventures, Sanofi Ventures, Bpifrance, and Seventure Partners. The company controls 25+ patent families covering 100+ bacterial species, including the earliest patent priority (2013) in CRISPR microbiome editing, and won a US patent interference that canceled five competing SNIPR Biome patents. As of the latest available data, Eligo employs approximately 35 people and is advancing EB005 toward a Phase 1b/2a clinical trial in acne.

Short descriptiontext

Eligo Bioscience is a Paris-based clinical-stage biotech developing the Eligobiotics platform for in vivo CRISPR-based gene editing of the microbiome, targeting inflammatory skin disorders, infectious diseases, and cardiac inflammation in patients via pharma partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome gene editing, CRISPR therapeutics, phage-derived delivery, genetic medicines, synthetic biology platform
Industry3 codes
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Microbiome Genetic Medicines
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Licensing and Partnership Deals
TypeLicensing Royalties
Description

Eligo generates revenue through strategic licensing agreements and research collaborations with pharmaceutical companies. Examples include the GSK deal (up to $224M in license fees and milestone payments) and ongoing pharma partnerships.

eligo.bio
2Non-dilutive Funding
TypeProfessional Services
Description

Government grants and non-dilutive funding from organizations including French government (France 2030), European Commission, CARB-X, and Bpifrance to support R&D activities.

eligo.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eligo Bioscience develops the Eligobiotics platform, a first-in-class proprietary modality that uses engineered phage-derived particles to deliver DNA payloads (CRISPR-Cas nucleases, base editors, or therapeutic genes) into bacterial populations of the microbiome for in vivo gene editing. The company applies this platform to develop therapeutic drug candidates targeting diseases driven by bacterial genes, including EB003 for STEC infection/Hemolytic Uremic Syndrome and EB005 for moderate to severe acne vulgaris (in partnership with GSK).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 99.7% editing efficiency achieved in animal gut microbiome models
+3 more records
Product overview1 text field

Eligo Bioscience has developed the GEM (Gene Editing of the Microbiome) platform, a first-in-class proprietary technology for in vivo gene editing of the microbiome. The platform encompasses three core modalities delivered through Eligobiotics®: SSAM (Sequence-Specific Anti-Microbials) for CRISPR-based bacterial killing, GEM for base editing, and FAME for therapeutic gene addition. The company's pipeline includes EB003 (lead candidate for STEC/HUS), EB005 (acne program with GSK), and programs targeting inflammatory cardiac diseases. Eligo is advancing toward clinical trials with the world's first topical CRISPR treatment for moderate to severe acne.

Product and service3 records
1Eligobiotics Platform
CategoryGene therapy platform
Description

A first-in-class proprietary modality using phage-derived particles to deliver DNA payloads encoding CRISPR systems into bacterial populations of the microbiome, enabling precise gene editing, killing, or functionalization of target bacteria in vivo. Licensed and co-developed with pharmaceutical partners for therapeutic applications.

2EB003
CategoryPipeline drug candidate
Description

Lead drug candidate using SSAM technology for treatment of Shiga-toxin producing E. coli (STEC) infection leading to Hemolytic Uremic Syndrome (HUS). Granted FDA Orphan Drug Designation and Rare Pediatric Disease designation; also received EMA Orphan Drug Designation.

3EB005
CategoryPipeline drug candidate
Description

Discovery program targeting moderate to severe acne vulgaris using Eligobiotics technology to precisely modify skin microbiome composition. Developed in partnership with GSK in a deal worth up to $224 million.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Biose Industries
Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-05-14
Description

Partnership with globally recognized CDMO specializing in microbial fermentation for GMP bioproduction scaling. Supports acceleration of clinical-grade manufacturing for Eligo's topical gene delivery vector.

eligo.bio
2Kantonsspital St. Gallen
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-09-13
Description

Strategic alliance to develop gene editing therapy for inflammatory cardiac diseases induced by bacterial mimicry. Combines Ludewig group's research on bacterial peptide mimics with Eligo's in vivo gene editing platform. Eligo gains access to patient samples, data, and animal models.

eligo.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-11
Description

Research and option agreement for advancement of Eligobiotics (EB005) for treatment of acne vulgaris using CRISPR-based therapeutic for strain-specific microbiome modulation. Eligo eligible to receive up to $224M in license fees and milestone payments plus royalties on global sales.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaboration hub; Eligo cofounders Prof. David Bikard (Synthetic Biology Lab Head) and Prof. Luciano Marraffini are from Rockefeller. Co-founder Tim Lu from MIT. Provides ongoing research collaboration and scientific expertise.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops defined bacterial consortia as live biotherapeutic products for immune-mediated diseases. Operates in the same microbiome therapeutics space with similar pharma partnership and licensing economics (e.g., Bristol Myers Squibb collaboration).

TypeEmerging player
Description

Clinical-stage base editing company developing precision genetic medicines. Comparable in base editing technology overlap with Eligo's GEM platform, though Beam targets human genome editing versus bacterial genome editing.

3Novome Biotechnologies
TypeDirect peer
Description

Engineered microbiome therapeutics company developing genetically modified bacteria for diseases including hyperoxaluria. Closely comparable in approach (genetic engineering of commensal bacteria) with similar platform-level licensing potential.

TypeDirect peer
Description

Clinical-stage biotech developing microbiome-targeted therapies including engineered B. infantis and small-molecule approaches to microbiome modulation. Comparable indication set (gastrointestinal, immunology) and partner-driven commercialization model.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia to treat disease. Targets similar indications including inflammatory and infectious diseases and serves as a benchmark for microbiome therapeutic development pathways and commercialization.

TypeBroad incumbent
Description

Ferring's microbiome division developing Microbiota Restoration Therapy for recurrent C. difficile infection. Acquired by Ferring, provides an example of a microbiome therapeutic reaching late-stage development and commercialization.

TypeDirect peer
Description

Direct competitor in CRISPR-based microbiome engineering. SNIPR Biome develops phage-delivered CRISPR antimicrobials to selectively kill bacteria, the same core modality as Eligo's SSAM platform. Eligo won a US patent interference against SNIPR Biome in 2021.

8Second Genome
TypeEmerging player
Description

Microbiome-focused drug discovery and development company identifying bacterial targets and small-molecule modulators. Comparable in microbiome therapeutic focus but uses small molecules rather than gene editing as the modality.

TypeEmerging player
Description

Clinical-stage CRISPR/Cas9 gene editing company co-founded by Eligo scientific cofounder Luciano Marraffini. Indirectly comparable through shared CRISPR therapeutic foundation; Intellia targets human gene editing while Eligo targets bacterial gene editing.

TypeDirect peer
Description

Microbiome therapeutics company developing Full-Spectrum Microbiota products for inflammatory and infectious diseases. Directly comparable clinical-stage peer pursuing microbiome-based therapies through pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eligo Bioscience

Microbiome Genetic Medicineseligo.bio

Eligo Bioscience is a Paris-based clinical-stage biotech developing the Eligobiotics platform for in vivo CRISPR-based gene editing of the microbiome, targeting inflammatory skin disorders, infectious diseases, and cardiac inflammation in patients via pharma partnerships.

What Eligo Bioscience does

Eligo Bioscience is a privately held, clinical-stage biotechnology company headquartered in Paris, France, developing a proprietary platform for in vivo gene editing of the microbiome. Founded in 2015 by CRISPR pioneers from The Rockefeller University and MIT, the company's Eligobiotics platform uses engineered phage-derived particles to deliver DNA payloads — including CRISPR-Cas nucleases, base editors, and therapeutic genes — directly into bacterial populations in the body, enabling precise, strain-specific modification or elimination of targeted bacteria without affecting beneficial commensals.

The platform comprises three core modalities: SSAM (Sequence-Specific Anti-Microbials) for CRISPR-based killing of harmful bacteria, GEM (Genome Editing of the Microbiome) for base editing of bacterial DNA without killing the cells, and FAME (Function Addition to the Microbiome) for programming commensal bacteria to express therapeutic proteins. Its lead programs are EB003, an oral candidate for Shiga-toxin producing E. coli infection leading to Hemolytic Uremic Syndrome (FDA Orphan Drug, Rare Pediatric Disease, and EMA Orphan Designations), and EB005, a topical candidate for moderate-to-severe acne vulgaris developed in partnership with GSK in a deal worth up to $224 million.

Eligo has no commercialized products and operates a pre-revenue business model that combines pharmaceutical licensing and co-development partnerships (e.g., GSK), non-dilutive grants from the French government (France 2030), the European Commission, and CARB-X, and venture financing from Khosla Ventures, Sanofi Ventures, Bpifrance, and Seventure Partners. The company controls 25+ patent families covering 100+ bacterial species, including the earliest patent priority (2013) in CRISPR microbiome editing, and won a US patent interference that canceled five competing SNIPR Biome patents. As of the latest available data, Eligo employs approximately 35 people and is advancing EB005 toward a Phase 1b/2a clinical trial in acne.

Eligo Bioscience firmographics

Firmographics
Name
Eligo Bioscience
Legal name
Eligo Bioscience SA
Website
https://eligo.bio
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Eligo Bioscience is a Paris-based clinical-stage biotech developing the Eligobiotics platform for in vivo CRISPR-based gene editing of the microbiome, targeting inflammatory skin disorders, infectious diseases, and cardiac inflammation in patients via pharma partnerships.
Ownership category
akta.pro rank

Eligo Bioscience industry classification

Industry
Product category
Microbiome Genetic Medicines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)

Keywords

  • Microbiome gene editing
  • CRISPR therapeutics
  • Phage-derived delivery
  • Genetic medicines
  • Synthetic biology platform

Where Eligo Bioscience is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Eligo Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing and Partnership Deals: Eligo generates revenue through strategic licensing agreements and research collaborations with pharmaceutical companies. Examples include the GSK deal (up to $224M in license fees and milestone payments) and ongoing pharma partnerships.
  2. Non-dilutive Funding: Government grants and non-dilutive funding from organizations including French government (France 2030), European Commission, CARB-X, and Bpifrance to support R&D activities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Eligo Bioscience product offering

Product offering

Core offering

Eligo Bioscience develops the Eligobiotics platform, a first-in-class proprietary modality that uses engineered phage-derived particles to deliver DNA payloads (CRISPR-Cas nucleases, base editors, or therapeutic genes) into bacterial populations of the microbiome for in vivo gene editing. The company applies this platform to develop therapeutic drug candidates targeting diseases driven by bacterial genes, including EB003 for STEC infection/Hemolytic Uremic Syndrome and EB005 for moderate to severe acne vulgaris (in partnership with GSK).

Product overview

Eligo Bioscience has developed the GEM (Gene Editing of the Microbiome) platform, a first-in-class proprietary technology for in vivo gene editing of the microbiome. The platform encompasses three core modalities delivered through Eligobiotics®: SSAM (Sequence-Specific Anti-Microbials) for CRISPR-based bacterial killing, GEM for base editing, and FAME for therapeutic gene addition. The company's pipeline includes EB003 (lead candidate for STEC/HUS), EB005 (acne program with GSK), and programs targeting inflammatory cardiac diseases. Eligo is advancing toward clinical trials with the world's first topical CRISPR treatment for moderate to severe acne.

Differentiator

Problem solved

Functional benefit

Products and services

  • Eligobiotics Platform A first-in-class proprietary modality using phage-derived particles to deliver DNA payloads encoding CRISPR systems into bacterial populations of the microbiome, enabling precise gene editing, killing, or functionalization of target bacteria in vivo. Licensed and co-developed with pharmaceutical partners for therapeutic applications.
  • EB003 Lead drug candidate using SSAM technology for treatment of Shiga-toxin producing E. coli (STEC) infection leading to Hemolytic Uremic Syndrome (HUS). Granted FDA Orphan Drug Designation and Rare Pediatric Disease designation; also received EMA Orphan Drug Designation.
  • EB005 Discovery program targeting moderate to severe acne vulgaris using Eligobiotics technology to precisely modify skin microbiome composition. Developed in partnership with GSK in a deal worth up to $224 million.

Quantifiable outcome

  • Up to 99.7% editing efficiency achieved in animal gut microbiome models
  • +3 more outcomes

Companies that use Eligo Bioscience

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Eligo Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Eligo Bioscience partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • Biose IndustriesmajorImplementation/ SI/ Consulting Partner · 14 May 2025Partnership with globally recognized CDMO specializing in microbial fermentation for GMP bioproduction scaling. Supports acceleration of clinical-grade manufacturing for Eligo's topical gene delivery vector.
  • Kantonsspital St. GallenmajorStrategic or Co-development Partner · 13 September 2022Strategic alliance to develop gene editing therapy for inflammatory cardiac diseases induced by bacterial mimicry. Combines Ludewig group's research on bacterial peptide mimics with Eligo's in vivo gene editing platform. Eligo gains access to patient samples, data, and animal models.
  • GSK (GlaxoSmithKline)coreStrategic or Co-development Partner · 11 January 2021Research and option agreement for advancement of Eligobiotics (EB005) for treatment of acne vulgaris using CRISPR-based therapeutic for strain-specific microbiome modulation. Eligo eligible to receive up to $224M in license fees and milestone payments plus royalties on global sales.
  • Institut PasteurcoreStrategic or Co-development PartnerAcademic collaboration hub; Eligo cofounders Prof. David Bikard (Synthetic Biology Lab Head) and Prof. Luciano Marraffini are from Rockefeller. Co-founder Tim Lu from MIT. Provides ongoing research collaboration and scientific expertise.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Eligo Bioscience competitors and assessment

Company assessment

Direct peers

  • Vedanta Biosciences: Develops defined bacterial consortia as live biotherapeutic products for immune-mediated diseases. Operates in the same microbiome therapeutics space with similar pharma partnership and licensing economics (e.g., Bristol Myers Squibb collaboration).
  • Novome Biotechnologies: Engineered microbiome therapeutics company developing genetically modified bacteria for diseases including hyperoxaluria. Closely comparable in approach (genetic engineering of commensal bacteria) with similar platform-level licensing potential.
  • Assembly Biosciences: Clinical-stage biotech developing microbiome-targeted therapies including engineered B. infantis and small-molecule approaches to microbiome modulation. Comparable indication set (gastrointestinal, immunology) and partner-driven commercialization model.
  • Seres Therapeutics: Clinical-stage microbiome therapeutics company developing defined bacterial consortia to treat disease. Targets similar indications including inflammatory and infectious diseases and serves as a benchmark for microbiome therapeutic development pathways and commercialization.
  • SNIPR Biome: Direct competitor in CRISPR-based microbiome engineering. SNIPR Biome develops phage-delivered CRISPR antimicrobials to selectively kill bacteria, the same core modality as Eligo's SSAM platform. Eligo won a US patent interference against SNIPR Biome in 2021.
  • Finch Therapeutics: Microbiome therapeutics company developing Full-Spectrum Microbiota products for inflammatory and infectious diseases. Directly comparable clinical-stage peer pursuing microbiome-based therapies through pharma partnerships.

Emerging players

  • Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines. Comparable in base editing technology overlap with Eligo's GEM platform, though Beam targets human genome editing versus bacterial genome editing.
  • Second Genome: Microbiome-focused drug discovery and development company identifying bacterial targets and small-molecule modulators. Comparable in microbiome therapeutic focus but uses small molecules rather than gene editing as the modality.
  • Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company co-founded by Eligo scientific cofounder Luciano Marraffini. Indirectly comparable through shared CRISPR therapeutic foundation; Intellia targets human gene editing while Eligo targets bacterial gene editing.

Broad incumbents

  • Rebiotix (Ferring Pharmaceuticals): Ferring's microbiome division developing Microbiota Restoration Therapy for recurrent C. difficile infection. Acquired by Ferring, provides an example of a microbiome therapeutic reaching late-stage development and commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Eligo Bioscience social profiles

Digital presence

Eligo Bioscience compliance and trust

Trust signal

Compliance3 records

Eligo Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eligo Bioscience leadership team

Management profile

Number of profiles

Profiles14 records

Eligo Bioscience funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eligo Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eligo Bioscience

What does Eligo Bioscience do?

Eligo Bioscience develops the Eligobiotics platform, a first-in-class proprietary modality that uses engineered phage-derived particles to deliver DNA payloads (CRISPR-Cas nucleases, base editors, or therapeutic genes) into bacterial populations of the microbiome for in vivo gene editing. The company applies this platform to develop therapeutic drug candidates targeting diseases driven by bacterial genes, including EB003 for STEC infection/Hemolytic Uremic Syndrome and EB005 for moderate to severe acne vulgaris (in partnership with GSK).

Is Eligo Bioscience a public or private company?

Eligo Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eligo Bioscience founded?

Eligo Bioscience was founded in 2015. It employs 11 to 50 people.

Where is Eligo Bioscience based?

Eligo Bioscience is headquartered in Paris, France, in the Europe region.

How does Eligo Bioscience make money?

Two revenue lines are on record. Pharmaceutical Licensing and Partnership Deals are the primary driver. The others are non-dilutive Funding.

Who are Eligo Bioscience's main competitors?

Direct peers on record are Vedanta Biosciences, Novome Biotechnologies, Assembly Biosciences, Seres Therapeutics, SNIPR Biome and Finch Therapeutics. Emerging players are Beam Therapeutics, Second Genome and Intellia Therapeutics. Rebiotix (Ferring Pharmaceuticals) is listed as a broad incumbent.

Does Eligo Bioscience have an API?

No public API is recorded for Eligo Bioscience.

What industry is Eligo Bioscience in?

Eligo Bioscience's product category is Microbiome Genetic Medicines. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldCRISPR-based approach fights pathogenic <em>E. coli</em>French researchers from Eligo Bioscience published a CRISPR-based antimicrobial approach, EB-003, for Shiga toxin-producing Escherichia coli (STEC) infections. STEC can cause bloody diarrhea and hemolytic uremic syndrome in up to 10%-15% of cases, and antibiotics are not recommended for treatment.Market Research FutureGermany Food Safety Testing Market Size, Share, Analysis 2035A market research report projects the Germany Food Safety Testing Market will grow from $1.2 billion in 2024 to $2.5 billion by 2035, representing a compound annual growth rate of 6.9% through the forecast period. Key developments include Eligo Bioscience's advancement of microbiome-based food safety solutions, Mérieux NutriSciences and Bureau Veritas expanding their testing services for stricter regulatory compliance, and Neogen Corporation completing an acquisition of a German food safety testing division in May 2023. The Federal Office of Consumer Protection and Food Safety has also updated regulations to align with international testing benchmarks, while increased consumer awareness and foodborne illness incidents continue to drive demand for food safety testing services across Germany's food and beverage industry.NewswireEligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-DermatologyEligo Bioscience received a $5 million French government grant to scale its topical gene delivery platform for immuno-dermatology. The funding will support bioproduction optimization with CDMO Biose Industries ahead of later-stage clinical trials. The company aims to expand its pipeline for chronic inflammatory skin diseases.EligoEligo Wins $5M Grant to Fast-Track Platform for Immuno-DermatologyEligo Bioscience received a $5 million French government grant to scale its topical gene delivery platform for immuno-dermatology. The funding will support bioprocess optimization ahead of later-stage trials, with a partnership with Biose Industries. The company aims to expand its pipeline for chronic inflammatory skin diseases.PR NewswireEligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-DermatologyEligo Bioscience received a $5 million French government grant to scale its topical gene delivery platform for immuno-dermatology. The funding will support bioproduction optimization with CDMO Biose Industries ahead of later-stage clinical trials. The company aims to expand its pipeline for chronic inflammatory skin diseases.GenengnewsPhage Therapy: Turning the Tables on BacteriaResearchers are engineering bacteriophages with CRISPR-Cas systems to target antibiotic-resistant bacteria, with companies Eligo Biosciences and Locus Biosciences leading the effort. Locus announced a $20 million license deal with Janssen Pharmaceuticals, and both companies plan clinical trials soon. The therapies aim to overcome antimicrobial resistance, which is projected to kill 10 million people annually by 2050.Pulse 2.0Eligo Bioscience: Gene-Editing Company Raises $30 MillionEligo Bioscience has secured $30 million in Series B funding led by Sanofi Ventures, with participation from Bpifrance and existing investors Khosla Ventures and Seventure Partners. The capital will accelerate the development of its flagship program EB005 for acne vulgaris through early clinical trials and facilitate expansion into oncology. Sanofi Ventures and Bpifrance representatives have joined Eligo's board of directors as part of the investment.Tech Funding NewsEligo Bioscience raises $30M to revolutionise genetic medicines — TFNEligo Bioscience has secured $30 million in a Series B funding round led by Sanofi Ventures to advance its gene-editing technologies. The capital will specifically accelerate the flagship program EB005 for acne treatment through pre-IND and IND activities, while also supporting expansion into oncology. This investment enables the company to produce clinical data in patients using its unique approach to in vivo delivery of genetic cargoes to the microbiome.